50 results on '"Lewis, Basil S."'
Search Results
2. Oral anticoagulation in patients with left ventricular thrombus – a systematic review and meta-analysis
- Author
-
Haller, Paul M, primary, Kazem, Niema, additional, Agewall, Stefan, additional, Borghi, Claudio, additional, Ceconi, Claudio, additional, Dobrev, Dobromir, additional, Cerbai, Elisabetta, additional, Grove, Erik Lerkevang, additional, Kaski, Juan Carlos, additional, Lewis, Basil S, additional, Niessner, Alexander, additional, Rocca, Bianca, additional, Rosano, Giuseppe, additional, Savarese, Gianluigi, additional, Schnabel, Renate, additional, Semb, Anne Grete, additional, Sossalla, Samuel, additional, Wassmann, Sven, additional, and Sulzgruber, Patrick, additional
- Published
- 2024
- Full Text
- View/download PDF
3. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from AHA
- Author
-
Kato, Eri Toda, primary, Ono, Koh, additional, and Lewis, Basil S, additional
- Published
- 2023
- Full Text
- View/download PDF
4. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA
- Author
-
Lewis, Basil S, primary
- Published
- 2023
- Full Text
- View/download PDF
5. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
- Author
-
Imazio, Massimo, Klein, Allan L., Brucato, Antonio, Abbate, Antonio, Arad, Michael, Cremer, Paul C., Insalaco, Antonella, LeWinter, Martin M., Lewis, Basil S., Lin, David, Luis, Sushil A., Nicholls, Stephen J., Sutej, Paul, Wasserstrum, Yishay, Clair, JoAnn, Agarwal, Indra, Wang, Sheldon, and Paolini, John F.
- Published
- 2024
- Full Text
- View/download PDF
6. GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity
- Author
-
Kato, Eri Toda, primary, Lewis, Basil S, additional, and Ono, Koh, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
- Author
-
Drexel, Heinz, primary, Tamargo, Juan, additional, Kaski, Juan Carlos, additional, Lewis, Basil S, additional, Saely, Christoph H, additional, Fraunberger, Peter, additional, Dobrev, Dobromir, additional, Komiyama, Maki, additional, Plattner, Thomas, additional, Agewall, Stefan, additional, and Hasegawa, Koji, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Pericardial Late Gadolinium Enhancement and Time to Recurrence: A Substudy from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis
- Author
-
Cremer, Paul C, primary, Lin, David, additional, Luis, Sushil A, additional, Petersen, John, additional, Abbate, Antonio, additional, Jellis, Christine L, additional, Kwon, Debbie, additional, Brucato, Antonio, additional, Fang, Fang, additional, Insalaco, Antonella, additional, LeWinter, Martin, additional, Lewis, Basil S, additional, Zou, Liangxing, additional, Nicholls, Stephen J, additional, Klein, Allan L, additional, Imazio, Massimo, additional, and Paolini, John F, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
- Author
-
Brucato, Antonio, primary, Wheeler, Alistair, additional, Luis, Sushil Allen, additional, Abbate, Antonio, additional, Cremer, Paul C, additional, Zou, Liangxing, additional, Insalaco, Antonella, additional, Lewinter, Martin, additional, Lewis, Basil S, additional, Lin, David, additional, Nicholls, Stephen, additional, Pancrazi, Massimo, additional, Klein, Allan L, additional, Imazio, Massimo, additional, and Paolini, John F, additional
- Published
- 2022
- Full Text
- View/download PDF
10. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting
- Author
-
Kato, Eri Toda, Ono, Koh, and Lewis, Basil S
- Published
- 2024
- Full Text
- View/download PDF
11. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events
- Author
-
Tamargo, Juan, primary, Kaski, Juan Carlos, additional, Kimura, Takeshi, additional, Barton, Jack Charles, additional, Yamamoto, Ko, additional, Komiyama, Maki, additional, Drexel, Heinz, additional, Lewis, Basil S, additional, Agewall, Stefan, additional, and Hasegawa, Koji, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Abstract 47: Tapering And Discontinuation Of Background Therapies During The Transition To Rilonacept Monotherapy In Rhapsody, A Phase 3 Clinical Trial Of Rilonacept In Patients With Recurrent Pericarditis
- Author
-
Brucato, Antonio, primary, Wheeler, Alistair, additional, Luis, Sushil A, additional, Abbate, Antonio, additional, Cremer, Paul C, additional, Fang, Fang, additional, Insalaco, Antonella, additional, Lewinter, Martin M, additional, Lewis, Basil S, additional, Lin, David, additional, Nicholls, Stephen J, additional, Chatfield, Jay B, additional, Klein, Allan L, additional, Imazio, Massimo, additional, and Paolini, John F, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
- Author
-
Eikelboom, John W, primary, Bosch, Jacqueline, additional, Connolly, Stuart J, additional, Tyrwitt, Jessica, additional, Fox, Keith A A, additional, Muehlhofer, Eva, additional, Neumann, Christoph, additional, Tasto, Christoph, additional, Bangdiwala, Shrikant I, additional, Diaz, Rafael, additional, Alings, Marco, additional, Dagenais, Gilles R, additional, Leong, Darryl P, additional, Lonn, Eva M, additional, Avezum, Alvaro, additional, Piegas, Leopoldo S, additional, Widimsky, Petr, additional, Parkhomenko, Alexander N, additional, Bhatt, Deepak L, additional, Branch, Kelley R H, additional, Probstfield, Jeffrey L, additional, Lopez-Jaramillo, Patricio, additional, Rydén, Lars, additional, Pogosova, Nana, additional, Keltai, Katalin, additional, Keltai, Matyas, additional, Ertl, Georg, additional, Stoerk, Stefan, additional, Dans, Antonio L, additional, Lanas, Fernando, additional, Liang, Yan, additional, Zhu, Jun, additional, Torp-Pedersen, Christian, additional, Maggioni, Aldo P, additional, Commerford, Patrick J, additional, Guzik, Tomasz J, additional, Vanassche, Thomas, additional, Verhamme, Peter, additional, O'Donnell, Martin, additional, Tonkin, Andrew M, additional, Varigos, John D, additional, Vinereanu, Dragos, additional, Felix, Camillo, additional, Kim, Jae-Hyung, additional, Ibrahim, Khairul S, additional, Lewis, Basil S, additional, Metsarinne, Kaj P, additional, Aboyans, Victor, additional, Steg, Phillippe Gabriel, additional, Hori, Masatsugu, additional, Kakkar, Ajay, additional, Anand, Sonia S, additional, Lamy, Andre, additional, Sharma, Mukul, additional, and Yusuf, Salim, additional
- Published
- 2022
- Full Text
- View/download PDF
14. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
- Author
-
Zeppenfeld, Katja, Tfelt-Hansen, Jacob, de Riva, Marta, Winkel, Bo Gregers, Behr, Elijah R, Blom, Nico A, Charron, Philippe, Corrado, Domenico, Dagres, Nikolaos, de Chillou, Christian, Eckardt, Lars, Friede, Tim, Haugaa, Kristina H, Hocini, Mélèze, Lambiase, Pier D, Marijon, Eloi, Merino, Jose L, Peichl, Petr, Priori, Silvia G, Reichlin, Tobias, Schulz-Menger, Jeanette, Sticherling, Christian, Tzeis, Stylianos, Verstrael, Axel, Volterrani, Maurizio, Cikes, Maja, Kirchhof, Paulus, Abdelhamid, Magdy, Aboyans, Victor, Arbelo, Elena, Arribas, Fernando, Asteggiano, Riccardo, Basso, Cristina, Bauer, Axel, Bertaglia, Emanuele, Biering-Sørensen, Tor, Blomström-Lundqvist, Carina, Borger, Michael A, Čelutkienė, Jelena, Cosyns, Bernard, Falk, Volkmar, Fauchier, Laurent, Gorenek, Bulent, Halvorsen, Sigrun, Hatala, Robert, Heidbuchel, Hein, Kaab, Stefan, Konradi, Aleksandra, Koskinas, Konstantinos C, Kotecha, Dipak, Landmesser, Ulf, Lewis, Basil S, Linhart, Ales, Løchen, Maja-Lisa, Lund, Lars H, Metzner, Andreas, Mindham, Richard, Nielsen, Jens Cosedis, Norekvål, Tone M, Patten, Monica, Prescott, Eva, Rakisheva, Amina, Remme, Carol Ann, Roca-Luque, Ivo, Sarkozy, Andrea, Scherr, Daniel, Sitges, Marta, Touyz, Rhian M, Van Mieghem, Nicolas, Velagic, Vedran, Viskin, Sami, Volders, Paul G A, Pediatrics, Physiology, ACS - Heart failure & arrhythmias, Paediatric Cardiology, Cardiology, and APH - Methodology
- Subjects
Genetic testing ,Cardiac magnetic resonance ,Sudden death ,Arrhythmias, Cardiac ,Ventricular tachycardia ,Primary electrical disease ,Guidelines ,Recommendations ,Chronic coronary artery disease ,Risk calculator ,Sudden cardiac death ,Death, Sudden, Cardiac ,Implantable cardioverter defibrillator ,Ventricular arrhythmia ,Humans ,Catheter ablation ,Anti-arrhythmic drugs ,Ventricular fibrillation ,Cardiology and Cardiovascular Medicine ,610 Medicine & health ,Cardiomyopathies ,Premature ventricular complex ,Risk stratification - Published
- 2022
15. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.
- Author
-
Brucato, Antonio, Wheeler, Alistair, Luis, Sushil Allen, Abbate, Antonio, Cremer, Paul C., Zou Liangxing, Insalaco, Antonella, Lewinter, Martin, Lewis, Basil S., Lin, David, Nicholls, Stephen, Pancrazi, Massimo, Klein, Allan L., Imazio, Massimo, Paolini, John F., and Zou, Liangxing
- Subjects
PERICARDITIS ,INSTITUTIONAL review boards - Abstract
Objective: Polypharmacy management of recurrent pericarditis (RP) often involves long-term therapies, often with negative effects. Slow tapering of oral therapies is often required to avoid recurrence. A post hoc analysis of the phase III trial Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes Study (RHAPSODY) evaluated investigator approaches to transitioning to IL-1 blockade monotherapy with rilonacept, which was hypothesised to allow accelerated withdrawal of common multidrug pericarditis regimens.Methods: RHAPSODY was a multicentre (Australia, Israel, Italy, USA), double-blind, placebo-controlled, randomised-withdrawal trial in adults and adolescents with RP. Investigators initiated rilonacept at the labelled dose level and discontinued oral pericarditis therapies during the 12-week run-in; randomised patients received study drug as monotherapy. Time to rilonacept monotherapy was quantified in patients receiving multidrug regimens at baseline who achieved rilonacept monotherapy during run-in.Results: In 86 enrolled patients, mean time to rilonacept monotherapy was 7.9 weeks, with no recurrences. Of these, 64% (n=55) entered on multidrug regimens: non-steroidal anti-inflammatory drugs (NSAIDs) plus colchicine (44% (24/55)), colchicine plus glucocorticoids (24% (13/55)), or NSAIDs, colchicine, plus glucocorticoids (33% (18/55)). Investigators transitioned patients receiving colchicine and glucocorticoids at baseline to rilonacept monotherapy without recurrence regardless of taper approach: sequential (n=14; median, 7.7 weeks) or concurrent (n=17; median, 8.0 weeks). Median time to rilonacept monotherapy was similar regardless of glucocorticoid dose and duration: ≤15 mg/day (n=21): 7.3 weeks; >15 mg/day (n=18): 8.0 weeks; long-term (≥28 days): 7.6 weeks.Conclusions: Rapid discontinuation of oral RP therapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.Trial Registration Number: NCT03737110. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
16. Are SGLT2 inhibitors effective against ‘all’ heart failure with preserved ejection fraction?
- Author
-
Hasegawa, Koji, primary and Lewis, Basil S, additional
- Published
- 2022
- Full Text
- View/download PDF
17. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
- Author
-
Drexel, Heinz, Lewis, Basil S, Rosano, Giuseppe M C, Saely, Christoph H, Tautermann, Gerda, Huber, Kurt, Dopheide, Joern F., Kaski, Juan Carlos, Mader, Arthur, Niessner, Alexander, Savarese, Gianluigi, Schmidt, Thomas A, Semb, AnneGrete, Tamargo, Juan, Wassmann, Sven, Kjeldsen, Keld Per, Agewall, Stefan, and Pocock, Stuart J
- Subjects
610 Medicine & health - Abstract
This review article aims to explain the important issues that data safety monitoring boards (DSMB) face when considering early termination of a trial and is specifically addressed to the needs of clinical and research cardiologists. We give an insight into the overall background and then focus on the three principal reasons for stopping trials, i.e. efficacy, futility, and harm. The statistical essentials are also addressed to familiarize clinicians with the key principles. The topic is further highlighted by numerous examples from lipid trials and antithrombotic trials. This is followed by an overview of regulatory aspects, including an insight into industry–investigator interactions. To conclude, we summarize the key elements that are the basis for a decision to stop a randomized clinical trial (RCT).
- Published
- 2021
18. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.
- Author
-
Saldarriaga, Clara, Atar, Dan, Stebbins, Amanda, Lewis, Basil S., Abidin, Imran Zainal, Blaustein, Robert O., Butler, Javed, Ezekowitz, Justin A., Hernandez, Adrian F., Lam, Carolyn S.P., O'Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., Anstrom, Kevin J., and Armstrong, Paul W.
- Abstract
Aims: Coronary artery disease (CAD) portends worse outcomes in heart failure (HF). We aimed to characterize patients with CAD and worsening HF with reduced ejection fraction (HFrEF) and evaluate post hoc whether vericiguat treatment effect varied according to CAD. Methods and results: Cox proportional hazards were generated for the primary endpoint of cardiovascular death or HF hospitalization (CVD/HFH). CAD was defined as previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. Of 5048 patients in VICTORIA with available data on CAD status, 2704 had CAD and were older, were more frequently male, diabetic, and had a lower glomerular filtration rate than those without CAD (all p <0.0001). Use of implantable cardioverter defibrillators and cardiac resynchronization therapy (CRT) was higher in patients with versus without CAD (33.5% vs. 21.1%; p <0.0001 and 16.3% vs. 12.8%; p = 0.0006). The primary endpoint of CVD/HFH was higher in those with versus without CAD (40.6 vs. 30.1/100 patient‐years; adjusted hazard ratio [HR] 1.23; p <0.001) as was all‐cause mortality (17.9% vs. 12.7%; adjusted HR 1.32; p <0.001). The primary outcome of CVD/HFH associated with vericiguat in patients with or without CAD was 38.8 versus 27.6 per 100 patient‐years and for placebo was 42.6 versus 32.7 per 100 patient‐years (interaction p = 0.78). Conclusion: In this post hoc study, CAD was associated with more CVD and HFH in patients with HFrEF and worsening HF. Vericiguat was beneficial and safe regardless of concomitant CAD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
- Author
-
Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen J, Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis E, Fauchier, Laurent, Filippatos, Gerasimos, Kalman, Jonathan M, La Meir, Mark, Lane, Deirdre A, Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory Y H, Pinto, Fausto J, Thomas, G Neil, Valgimigli, Marco, Van Gelder, Isabelle C, Van Putte, Bart P, Watkins, Caroline L, Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, A John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry J G M, Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Fitzsimons, Donna, Folliguet, Thierry, Gale, Chris P, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo A, Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil S, Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia V, Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto F E, Petersen, Steffen E, Piccini, Jonathan P, Popescu, Bogdan A, Pürerfellner, Helmut, Richter, Dimitrios J, Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate B, Simpson, Iain A, Shlyakhto, Evgeny, Sinner, Moritz F, Steffel, Jan, Sousa-Uva, Miguel, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian M, Neil Thomas, G, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cardiovascular Centre (CVC), Surgical clinical sciences, and Cardiac Surgery
- Subjects
left atrial ablation ,left atrial appendage occlusion ,AF surgery ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Management of atrial fibrillation ,030204 cardiovascular system & hematology ,Cardioversion ,VITAMIN-K ANTAGONIST ,surgery ,chemistry.chemical_compound ,0302 clinical medicine ,cardioversion ,Edoxaban ,QUALITY-OF-LIFE ,antiarrhythmic drugs ,OBSTRUCTIVE SLEEP-APNEA ,catheter ablation ,RADIOFREQUENCY CATHETER ABLATION ,Medicine ,atrial fibrillation ,030212 general & internal medicine ,anticoagulation ,reproductive and urinary physiology ,ComputingMilieux_MISCELLANEOUS ,pulmonary vein isolation ,0303 health sciences ,rhythm control ,EACTS ,HEART RHYTHM SOCIETY ,recommendations ,Atrial fibrillation ,General Medicine ,non-Vitamin K antagonist oral anticoagulants ,Vitamin K antagonist ,PULMONARY-VEIN ISOLATION ,stroke ,3. Good health ,2020 ESC Guidelines ,Dronedarone ,vitamin K antagonists ,Cardiothoracic surgery ,Cardio-Thoracic Surgery ,embryonic structures ,DIRECT ORAL ANTICOAGULANTS ,cardiovascular system ,Cardiology ,Dose reduction ,biological phenomena, cell phenomena, and immunity ,Cardiology and Cardiovascular Medicine ,medicine.drug ,Quinidine ,medicine.medical_specialty ,medicine.drug_class ,non-vitamin K antagonist oral anticoagulants ,PERCUTANEOUS CORONARY INTERVENTION ,Renal function ,macromolecular substances ,ABC pathway ,Guidelines ,rate control ,screening ,upstream therapy ,Vitamin K antagonists ,B700 ,03 medical and health sciences ,Internal medicine ,Diseases of the circulatory (Cardiovascular) system ,cardiovascular diseases ,030304 developmental biology ,urogenital system ,business.industry ,medicine.disease ,TRANSIENT ISCHEMIC ATTACK ,ANTIARRHYTHMIC-DRUG-THERAPY ,chemistry ,030228 respiratory system ,Concomitant ,RC666-701 ,business - Abstract
Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight
- Published
- 2021
20. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy
- Author
-
Aboyans, Victor, Bauersachs, Rupert, Mazzolai, Lucia, Brodmann, Marianne, Palomares, José F Rodriguez, Debus, Sebastian, Collet, Jean-Philippe, Drexel, Heinz, Espinola-Klein, Christine, Lewis, Basil S, Roffi, Marco, Sibbing, Dirk, Sillesen, Henrik, Stabile, Eugenio, Schlager, Oliver, and Carlo, Marco De
- Subjects
FIBRINOLYTIC agents ,PERIPHERAL vascular diseases ,THROMBOSIS ,CARDIOVASCULAR diseases ,ANTICOAGULANTS - Abstract
The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice. In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the basis for long-term antithrombotic treatment in patients with aortic or peripheral arterial diseases. Its association with another antiplatelet agent or low-dose anticoagulants will be discussed, based on patient's ischaemic and bleeding risk as well therapeutic paths (e.g. endovascular therapy). This consensus document aims to provide a guidance for antithrombotic therapy according to arterial disease localizations and clinical presentation. However, it cannot substitute multidisciplinary team discussions, which are particularly important in patients with uncertain ischaemic/bleeding balance. Importantly, since this balance evolves over time in an individual patient, a regular reassessment of the antithrombotic therapy is of paramount importance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA
- Author
-
Lewis, Basil S
- Published
- 2024
- Full Text
- View/download PDF
22. Factor XIa inhibitors: collecting the clinical evidence
- Author
-
Lewis, Basil S and Hasegawa, Koji
- Published
- 2024
- Full Text
- View/download PDF
23. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy
- Author
-
Drexel, Heinz, Pocock, Stuart J, Lewis, Basil S, Saely, Christoph H, Kaski, Juan Carlos, Rosano, Giuseppe M C, Tautermann, Gerda, Huber, Kurt, Dopheide, Joern F, Mader, Arthur, Niessner, Alexander, Savarese, Gianluigi, Schmidt, Thomas A, Semb, Anne Grete, Tamargo, Juan, Wassmann, Sven, Clodi, Martin, Kjeldsen, Keld Per, and Agewall, Stefan
- Published
- 2022
- Full Text
- View/download PDF
24. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
- Author
-
De Caterina, Raffaele, Patti, Giuseppe, Westerbergh, Johan, Horowitz, John, Ezekowitz, Justin A, Lewis, Basil S, Lopes, Renato D, McMurray, John J V, Atar, Dan, Bahit, M Cecilia, Keltai, Matyas, López-Sendón, José L, Ruzyllo, Witold, Granger, Christopher B, Alexander, John H, and Wallentin, Lars
- Published
- 2022
- Full Text
- View/download PDF
25. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing
- Author
-
El Hadidi, Seif, Rosano, Giuseppe, Tamargo, Juan, Agewall, Stefan, Drexel, Heinz, Kaski, Juan Carlos, Niessner, Alexander, Lewis, Basil S, Coats, Andrew J S, and Savarese, Gianluigi
- Abstract
Heart failure (HF) is a chronic debilitating and potentially life-threatening condition. HF patients are usually at high risk of polypharmacy and consequently, potentially inappropriate prescribing leading to poor clinical outcomes. Based on the published literature, a comprehensive HF-specific prescribing review tool is compiled to avoid medications that may cause HF or harm HF patients and to optimize the prescribing practice of HF guideline-directed medical therapies. Recommendations are made in line with the last versions of European Society of Cardiology (ESC) guidelines, ESC position papers, scientific evidence, and experts’ opinions.
- Published
- 2022
- Full Text
- View/download PDF
26. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
- Author
-
Magavern, Emma Forton, Kaski, Juan Carlos, Turner, Richard M, Drexel, Heinz, Janmohamed, Azara, Scourfield, Andrew, Burrage, Daniel, Floyd, Christopher N, Adeyeye, Elizabeth, Tamargo, Juan, Lewis, Basil S, Kjeldsen, Keld Per, Niessner, Alexander, Wassmann, Sven, Sulzgruber, Patrick, Borry, Pascal, Agewall, Stefan, Semb, Anne Grete, Savarese, Gianluigi, Pirmohamed, Munir, and Caulfield, Mark J
- Abstract
There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. However, there is no common position taken by international cardiovascular societies to unite diverse availability, interpretation, and application of such data, nor is there recognition of the challenges of variation in clinical practice between countries within Europe. Aside from the considerable barriers to implementing pharmacogenomic testing and the complexities of clinically actioning results, there are differences in the availability of resources and expertise internationally within Europe. Diverse legal and ethical approaches to genomic testing and clinical therapeutic application also require serious thought. As direct-to-consumer genomic testing becomes more common, it can be anticipated that data may be brought in by patients themselves, which will require critical assessment by the clinical cardiovascular prescriber. In a modern, pluralistic and multi-ethnic Europe, self-identified race/ethnicity may not be concordant with genetically detected ancestry and thus may not accurately convey polymorphism prevalence. Given the broad relevance of pharmacogenomics to areas, such as thrombosis and coagulation, interventional cardiology, heart failure, arrhythmias, clinical trials, and policy/regulatory activity within cardiovascular medicine, as well as to genomic and pharmacology subspecialists, this position statement attempts to address these issues at a wide-ranging level.
- Published
- 2022
- Full Text
- View/download PDF
27. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
- Author
-
Magavern, Emma F, Kaski, Juan Carlos, Turner, Richard M, Drexel, Heinz, Janmohamed, Azara, Scourfield, Andrew, Burrage, Daniel, Floyd, Christopher N, Adeyeye, Elizabeth, Tamargo, Juan, Lewis, Basil S, Kjeldsen, Keld Per, Niessner, Alexander, Wassmann, Sven, Sulzgruber, Patrick, Borry, Pascal, Agewall, Stefan, Semb, Anne Grete, Savarese, Gianluigi, Pirmohamed, Munir, and Caulfield, Mark J
- Abstract
Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.
- Published
- 2022
- Full Text
- View/download PDF
28. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
- Author
-
Krogager, Maria Lukács, Kragholm, Kristian, Thomassen, Jesper Qvist, Søgaard, Peter, Lewis, Basil S, Wassmann, Sven, Baumgartner, Iris, Ceconi, Claudio, Schmidt, Thomas Andersen, Kaski, Juan Carlos, Drexel, Heinz, Semb, Anne Grete, Agewall, Stefan, Niessner, Alexander, Savarese, Gianluigi, Kjeldsen, Keld Per, Borghi, Claudio, Tamargo, Juan, and Torp-Pedersen, Christian
- Abstract
Hypokalaemia is common in patients with cardiovascular disease. In this review, we emphasize the importance of tight potassium regulation in patients with cardiovascular disease based on findings from observational studies. To enhance the understanding, we also describe the mechanisms of potassium homeostasis maintenance, the most common causes of hypokalaemia and present strategies for monitoring and management of low potassium levels. We propose elevation of potassium in asymptomatic patients with lower normal concentrations and concurrent cardiovascular disease. These proposals are intended to assist clinicians until more evidence is available.
- Published
- 2021
- Full Text
- View/download PDF
29. 2020 Ghidul ESC pentru managementul sindroamelor coronariene acute fără supradenivelare persistentă de segment: Grupul de lucru asupra managementului sindroamelor coronariene acute fără supradenivelare persistentă de segment ST din cadrul Societăţii Europene de Cardiologie
- Author
-
Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak L., Dendale, Paul, Dorobanţu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris P., Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil S., Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, and Mueller, Christian
- Subjects
- *
NON-ST elevated myocardial infarction , *PRASUGREL , *CEREBROVASCULAR disease , *LDL cholesterol , *EVEROLIMUS , *PERCUTANEOUS coronary intervention , *MYOCARDIAL infarction , *CORONARY care units - Published
- 2021
30. Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial.
- Author
-
Gibson CM, Duffy D, Bahit MC, Chi G, White H, Korjian S, Alexander JH, Lincoff AM, Heise M, Kingwell BA, Nicolau JC, Lopes RD, Cornel JH, Lewis BS, Vinereanu D, Goodman SG, Bode C, Steg PG, Libby P, Sacks FM, Bainey KR, Ridker PM, Mahaffey KW, Aylward P, Nicholls SJ, Pocock SJ, Mehran R, and Harrington RA
- Abstract
Background and Aims: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given the well-established relationship between higher low-density lipoprotein cholesterol (LDL-C) and plaque burden, as well as greater risk reductions seen with PCSK9 inhibitors in patients with baseline LDL-C ≥100 mg/dL on statin therapy, the efficacy of CSL112 may be influenced by baseline LDL-C., Methods: Overall, 18,219 patients with acute MI, multivessel coronary artery disease, and additional risk factors were randomized to either four weekly infusions of 6 g CSL112 or placebo. This exploratory post-hoc analysis evaluated cardiovascular outcomes by baseline LDL-C in patients prescribed guideline-directed statin therapy at the time of randomization (n=15,731)., Results: As baseline LDL-C increased, risk of the primary endpoint at 90 days lowered in those treated with CSL112 compared with placebo. In patients with LDL-C ≥100 mg/dL at randomization, there was a significant risk reduction of cardiovascular death, MI, or stroke in the CSL112 vs. placebo group at 90, 180, and 365 days (hazard ratio 0.69 [0.53-0.90], 0.71 [0.57-0.88], and 0.78 [0.65-0.93]). In contrast, there was no difference between treatment groups among those with LDL-C <100 mg/dL at baseline., Conclusions: In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
31. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.
- Author
-
Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, Kamel H, Lewis BS, Cornel JH, Kowey PR, Horrow J, Strony J, Plotnikov AN, Li D, Weng S, Donahue J, Gibson CM, Steg PG, Mehran R, Weitz JI, Johnston SC, Hankey GJ, Harrington RA, and Lam CSP
- Abstract
Background: Direct oral anticoagulants are the standard of care for stroke prevention in eligible patients with atrial fibrillation and atrial flutter; however, bleeding remains a significant concern, limiting their use. Milvexian is an oral Factor XIa inhibitor that may offer similar anticoagulant efficacy with less bleeding risk., Methods: LIBREXIA AF (NCT05757869) is a global phase III, randomized, double-blind, parallel-group, event-driven trial to compare milvexian with apixaban in participants with atrial fibrillation or atrial flutter. Participants are randomly assigned to milvexian 100 mg or apixaban (5 mg or 2.5 mg per label indication) twice daily. The primary efficacy objective is to evaluate if milvexian is noninferior to apixaban for the prevention of stroke and systemic embolism. The principal safety objective is to evaluate if milvexian is superior to apixaban in reducing the endpoint of International Society of Thrombosis and Hemostasis (ISTH) major bleeding events and the composite endpoint of ISTH major and clinically relevant nonmajor (CRNM) bleeding events. In total, 15,500 participants from approximately 1,000 sites in over 30 countries are planned to be enrolled. They will be followed until both 430 primary efficacy outcome events and 530 principal safety events are observed, which is estimated to take approximately 4 years., Conclusion: The LIBREXIA AF study will determine the efficacy and safety of the oral Factor XIa inhibitor milvexian compared with apixaban in participants with either atrial fibrillation or atrial flutter., Trial Registration: ClinicalTrials.gov NCT05757869., Competing Interests: Disclosures SSJ reports consulting fees from Bristol Myers Squibb, ARTIS Ventures, and Broadview Ventures outside of the submitted work. KWM’s financial disclosures can be reviewed at http://med.stanford.edu/profiles/kenneth-mahaffey. KSP is a member of The Thrombosis Research Institute which has received institutional research grant support from Anthos Therapeutics and Bayer Pharmaceuticals. She has received honoraria from Element Science and Artivion, Inc. WS has received honoraria (>10K USD) from Daiichi Sankyo, Nippon Boehringer Ingelheim, and Pfizer Japan, and research grants (>50K USD) from Daiichi Sankyo and Nippon Boehringer Ingelheim. CTR reports Research Grants through Institution from: Athos, AstraZeneca, Daiichi Sankyo, Janssen and Novartis. Honoraria for scientific ad boards and consulting from: Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen and Pfizer. He is a member of The TIMI Study Group which has received institutional research grant support through Brigham and Women's Hospital from: Abbott, Abiomed, Inc, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis Pharmaceuticals, Inc, Janssen Research & Development, LLC, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc, Roche, Saghmos Therapeutics, Inc, Siemens Healthcare Diagnostics, Inc, Softcell Medical Limited, The Medicines Company, Verve Therapeutics, Inc, Zora Biosciences. PRK reports consultancy from Anthos, J&J, BMS and Bayer. GS has received research grants from Amarin, AstraZeneca, and Sanofi; has participated in clinical trials, consulting, or speaking for Amarin, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Idorsia, Janssen, Novartis, Novo Nordisk, PhaseBio, Pfizer, and Sanofi; is a Senior Associate Editor at Circulation; and serves as the CMO for Bioquantis. RM reports institutional research payments from: Abbott, Affluent Medical, Alleviant Medical, Amgen, AstraZeneca, BAIM, Beth Israel Deaconess Medical Center, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CERC, Chiesi, Concept Medical, Daiichi Sankyo, Duke, Faraday, Idorsia, Janssen, MedAlliance, Medscape, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Pi-Cardia, Protembis, RM Global Bioaccess Fund Management, Sanofi; consultant to Affluent Medical, Boehringer Ingelheim, Chiesi USA, Cordis, Esperion Science/Innovative Biopharma, Gaffney Events, Educational Trust, Global Clinical Trial Partners, Ltd., IQVIA, Medscape/WebMD Global, NovoNordisk, PeerView Institute for Medical Education, TERUMO Europe N.V., Radcliffe and honoararia from AMA and ACC. SCJ has received research support from Jansen, BMS, and AstraZeneca. GJH reports personal honoraria outside the submitted work from the American Heart Association (Associate Editor, Circulation), Bristol Myers Squibb (Steering Committee, AXIOMATIC-SSP trial of milvexian [factor XIa inhibitor] for secondary stroke prevention) and Janssen (Co-chair, Executive Committee, Librexia Stroke trial of milvexian for secondary stroke prevention). RAH has received research grants/contracts from NHLBI (ISCHEMIA), Duke/PCORI (ADAPTABLE), Janssen (Factor Xia inhibitor), CSL (HDL), Baim Institute, UColorado, Harvard (BWH), and Merck; has served as a consultant/advisor for NHLBI (COVID/CONNECTS), Atropos Health, Bitterroot Bio, Bristol Myers Squibb, Bridge Bio, Chiesi, CSL Behring, Edwards Lifesciences Corp, Element Science, Foresight, Merck, and WebMD; and serves on the Board of Directors for AHA and Cytokinetics. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has Received research support from Novo Nordisk and Roche Diagnostics; has Served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Hanmi, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as Co-founder and nonexecutive director of Us2.ai. The remaining authors report no relevant disclosures or competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis.
- Author
-
Haller PM, Kazem N, Agewall S, Borghi C, Ceconi C, Dobrev D, Cerbai E, Grove EL, Kaski JC, Lewis BS, Niessner A, Rocca B, Rosano G, Savarese G, Schnabel RB, Semb AG, Sossalla S, Wassmann S, and Sulzgruber P
- Subjects
- Humans, Administration, Oral, Treatment Outcome, Risk Factors, Anticoagulants adverse effects, Anticoagulants administration & dosage, Heart Ventricles drug effects, Female, Risk Assessment, Male, Stroke mortality, Stroke diagnosis, Stroke prevention & control, Aged, Factor Xa Inhibitors adverse effects, Factor Xa Inhibitors administration & dosage, Vitamin K antagonists & inhibitors, Middle Aged, Thrombosis mortality, Thrombosis drug therapy, Thrombosis prevention & control, Thrombosis diagnosis, Hemorrhage chemically induced, Heart Diseases mortality, Heart Diseases diagnosis, Heart Diseases drug therapy, Heart Diseases complications
- Abstract
Aims: Direct oral anticoagulants (DOACs) are increasingly used off-label to treat patients with left ventricular thrombus (LVT). We analysed available meta-data comparing DOACs and vitamin K antagonists (VKAs) for efficacy and safety., Methods: We conducted a systematic search and meta-analysis of observational and randomized data comparing DOACs vs. VKAs in patients with LVT. Endpoints of interest were stroke or systemic embolism, thrombus resolution, all-cause death, and a composite bleeding endpoint. Estimates were pooled using a random-effects model meta-analysis, and their robustness was investigated using sensitivity and influential analyses., Results: We identified 22 articles (18 observational studies, 4 small randomized clinical trials) reporting on a total of 3587 patients (2489 VKA vs. 1098 DOAC therapy). The pooled estimates for stroke or systemic embolism [odds ratio (OR): 0.81; 95% confidence interval (CI): 0.57, 1.15] and thrombus resolution (OR: 1.12; 95% CI: 0.86, 1.46) were comparable, and there was low heterogeneity overall across the included studies. The use of DOACs was associated with lower odds of all-cause death (OR: 0.65; 95% CI: 0.46, 0.92) and a composite bleeding endpoint (OR: 0.67; 95% CI: 0.47, 0.97). A risk of bias was evident particularly for observational reports, with some publication bias suggested in funnel plots., Conclusion: In this comprehensive analysis of mainly observational data, the use of DOACs was not associated with a significant difference in stroke or systemic embolism, or thrombus resolution, compared with VKA therapy. The use of DOACs was associated with a lower rate of all-cause death and fewer bleeding events. Adequately sized randomized clinical trials are needed to confirm these findings, which could allow a wider adoption of DOACs in patients with LVT., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
33. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.
- Author
-
Khan MS, Butler J, Young R, Lewis BS, Escobedo J, Refsgaard J, Reyes E, Roessig L, Blaustein RO, Lam CSP, Voors AA, Ponikowski P, Anstrom KJ, and Armstrong PW
- Abstract
Background: Type 2 diabetes mellitus (T2DM) significantly worsens heart failure (HF) prognosis., Objectives: This study sought to investigate the impact of T2DM on outcomes in patients enrolled in VICTORIA and assess the efficacy of vericiguat in patients with and without T2DM., Methods: Patients with HF with reduced ejection fraction were randomized to receive vericiguat or placebo in addition to standard therapy. The primary outcome was a composite of cardiovascular death or first heart failure hospitalization (HFH). A Cox proportional hazards model was used to calculate HRs and 95% CIs to assess if the effect of vericiguat differed by history of T2DM., Results: Of 5,050 patients enrolled, 3,683 (72.9%) had glycosylated hemoglobin (HbA
1c ) measured at baseline. Of these, 2,270 (61.6%) had T2DM, 741 (20.1%) had pre-T2DM, 449 (12.2%) did not have T2DM, and 178 (4.8%) had undiagnosed T2DM. The risks of the primary outcome, HFH, and all-cause and cardiovascular mortality were high across all categories. The efficacy of vericiguat on the primary outcome did not differ in patients stratified by T2DM by history (HR: 0.92; 95% CI: 0.81-1.04), T2DM measured by HbA1c (HR: 0.77; 95% CI: 0.49-1.20), and pre-T2DM measured by HbA1c (HR: 0.88; 95% CI: 0.68-1.13) and in those with normoglycemia (HR: 1.02: 95% CI: 0.75-1.39; P for interaction = 0.752). No significant differences were observed in subgroups with respect to the efficacy of vericiguat on HFH and all-cause or cardiovascular death., Conclusions: In this post hoc analysis of VICTORIA, vericiguat compared with placebo significantly reduced the risk of cardiovascular death or HFH in patients with worsening HF with reduced ejection fraction regardless of T2DM status. (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction [HFrEF] [Mk-1242-001] [VICTORIA]; NCT02861534)., Competing Interests: Funding Support and Author Disclosures VICTORIA was funded by Bayer and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, New Jersey, USA. Dr Khan has served as an Advisory Board Member for Bayer. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Roessig has been an employee of Bayer AG. Dr Blaustein has been an employee of Merck & Co, Inc. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; has received consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus; has patent PCT/SG2016/050217 pending and patent 16/216929 pending; and is cofounder and nonexecutive director of eKo.ai. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ponikowski has received research grants, has received consulting fees, and has served on the Speakers Bureau for Bayer, MSD, Servier, Novartis, Vifor Pharma Ltd, BMS, Boehringer Ingelheim, Respicardia, AstraZeneca, Cibiem, RenalGuardSolution, and Berlin Chemie. Dr Anstrom has received research grants from Merck and the National Institutes of Health. Dr Armstrong has received consulting fees from Merck, Bayer, Boehringer Ingelheim, and Novo Nordisk and research grants from Merck, Bayer, Boehringer Ingelheim/Eli Lilly, and CSL Limited. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
34. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
- Author
-
Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, and Harrington RA
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Cardiovascular Diseases etiology, Cardiovascular Diseases metabolism, Cardiovascular Diseases mortality, Cardiovascular Diseases prevention & control, Coronary Artery Disease drug therapy, Coronary Artery Disease complications, Double-Blind Method, Infusions, Intravenous, Kaplan-Meier Estimate, Recurrence, Secondary Prevention, Stroke prevention & control, Risk Factors, Apolipoprotein A-I administration & dosage, Apolipoprotein A-I blood, Lipoproteins, HDL blood, Lipoproteins, HDL metabolism, Myocardial Infarction complications, Myocardial Infarction drug therapy, Myocardial Infarction metabolism, Myocardial Infarction mortality
- Abstract
Background: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear., Methods: We conducted an international, double-blind, placebo-controlled trial involving patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors. Patients were randomly assigned to receive either four weekly infusions of 6 g of CSL112 or matching placebo, with the first infusion administered within 5 days after the first medical contact for the acute myocardial infarction. The primary end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes from randomization through 90 days of follow-up., Results: A total of 18,219 patients were included in the trial (9112 in the CSL112 group and 9107 in the placebo group). There was no significant difference between the groups in the risk of a primary end-point event at 90 days of follow-up (439 patients [4.8%] in the CSL112 group vs. 472 patients [5.2%] in the placebo group; hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.05; P = 0.24), at 180 days of follow-up (622 patients [6.9%] vs. 683 patients [7.6%]; hazard ratio, 0.91; 95% CI, 0.81 to 1.01), or at 365 days of follow-up (885 patients [9.8%] vs. 944 patients [10.5%]; hazard ratio, 0.93; 95% CI, 0.85 to 1.02). The percentage of patients with adverse events was similar in the two groups; a higher number of hypersensitivity events was reported in the CSL112 group., Conclusions: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
35. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting.
- Author
-
Kato ET, Ono K, and Lewis BS
- Subjects
- United States epidemiology, Humans, American Heart Association, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Myocardial Infarction diagnosis, Myocardial Infarction drug therapy
- Published
- 2024
- Full Text
- View/download PDF
36. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA.
- Author
-
Lewis BS
- Subjects
- Humans, Gene Editing, Proprotein Convertase 9 genetics, Cardiovascular System
- Published
- 2024
- Full Text
- View/download PDF
37. Factor XIa inhibitors: collecting the clinical evidence.
- Author
-
Lewis BS and Hasegawa K
- Subjects
- Humans, Factor XIa, Protease Inhibitors
- Published
- 2024
- Full Text
- View/download PDF
38. GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity.
- Author
-
Kato ET, Lewis BS, and Ono K
- Subjects
- Humans, Stroke Volume, Obesity complications, Obesity diagnosis, Obesity drug therapy, Glucagon-Like Peptide-1 Receptor Agonists, Heart Failure diagnosis, Heart Failure drug therapy
- Published
- 2023
- Full Text
- View/download PDF
39. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
- Author
-
Drexel H, Tamargo J, Kaski JC, Lewis BS, Saely CH, Fraunberger P, Dobrev D, Komiyama M, Plattner T, Agewall S, and Hasegawa K
- Subjects
- Humans, Triglycerides, Cholesterol, LDL, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypertriglyceridemia diagnosis, Hypertriglyceridemia drug therapy, Hypertriglyceridemia epidemiology, Atherosclerosis drug therapy
- Abstract
Despite the atherosclerotic cardiovascular disease (ASCVD) risk reduction achieved by low-density lipoprotein cholesterol (LDL-C) lowering therapy, residual ASCVD risk still exists. Previous epidemiological studies have suggested high plasma triglyceride (TG) levels as a risk factor or risk marker for ASCVD independent of LDL-C levels. In this review, we highlighted the underlying pathophysiology of hypertriglyceridaemia, the mechanistic action of therapeutic agents, the interpretation of conflicting results on recent clinical trials, and the present options for primary and secondary prevention. The benefits of fibrates-induced reduction in TG and increase in high-density lipoprotein cholesterol might outweigh the disadvantages of increasing LDL-C levels in primary prevention. In secondary CVD prevention, using eicosapentaenoic acid without docosahexaenoic acid, in addition to statins, will be beneficial. This comprehensive review may prove useful for the development of novel approaches that target hypertriglyceridaemia in future., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
40. Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis.
- Author
-
Cremer PC, Lin D, Luis SA, Petersen J, Abbate A, Jellis CL, Kwon D, Brucato A, Fang F, Insalaco A, LeWinter M, Lewis BS, Zou L, Nicholls SJ, Klein AL, Imazio M, and Paolini JF
- Abstract
Aims: In this protocol-predefined substudy of the RHAPSODY trial, the primary aim was to assess whether pericardial late gadolinium enhancement (LGE) was associated with time to pericarditis recurrence., Methods and Results: RHAPSODY was a Phase 3 double-blind, placebo-controlled, randomized-withdrawal trial that demonstrated the efficacy of rilonacept in recurrent pericarditis (RP). Patients with a history of multiple RP and an active recurrence were enrolled and had the option to participate in a cardiac magnetic resonance (CMR) imaging substudy. CMRs were interpreted by a blinded independent core laboratory with prespecified criteria to define pericardial LGE. Compared to patients with trace or mild pericardial LGE ( n = 9), patients with moderate or severe pericardial LGE ( n = 16) generally had a higher number of recurrent episodes per year (5.3 vs. 3.9) and a higher mean CRP level (3.6 vs. 1.1 mg/dL). Overall, 10/14 (71.4%) who received a placebo had a recurrence compared to 0/11 (0%) who received rilonacept. In patients randomized to placebo who had moderate or severe pericardial LGE, the median time to recurrence was 4.2 weeks compared to 10.7 weeks in patients who had trace or mild pericardial LGE. At the conclusion of the event-driven randomized-withdrawal period, among patients receiving a placebo, 5/7 (71.4%) with trace or mild pericardial LGE and 5/7 (71.4%) with moderate or severe pericardial LGE had a recurrence., Conclusions: Among patients with multiple RP, these preliminary findings support the concept of pericardial LGE as an imaging biomarker that may inform the duration of treatment and risk of recurrence with cessation of therapy and larger studies should be considered., Clinicaltrialsgov Identifier: NCT03737110., Competing Interests: P.C. Cremer: Cremer reports grants and personal fees from Kiniksa Pharmaceuticals; grants from Novartis Pharmaceuticals; and personal fees from SOBI Pharmaceuticals outside the submitted work. D. Lin: None. S.A. Luis: Luis reports consultant fees for Kiniksa Pharmaceuticals, SOBI Pharmaceuticals, and Medtronic. J. Petersen: None. A. Abbate: Abbate reports grants and personal fees from Kiniksa Pharmaceuticals during the conduct of the study; grants and personal fees from Olatec, Serpin, Novartis, and Janssen; and personal fees from Novo-Nordisk and Cromos Pharma outside the submitted work. C.L. Jellis: None. D. Kwon: None. A. Brucato: Brucato reports institutional funding from Kiniksa Pharmaceuticals as an investigative site; an unrestricted research grant from SOBI and ACARPIA; and travel and accommodation for the advisory committee from SOBI and Kiniksa Pharmaceuticals. F. Fang: Fang reports personal fees and others from Kiniksa Pharmaceuticals outside the submitted work at the time the study was conducted. A. Insalaco: Insalaco reports personal fees from SOBI. M. LeWinter: LeWinter reports grants and advisory board, consulting, and other fees from Kiniksa Pharmaceuticals outside the submitted work and consulting fees from SOBI Pharmaceuticals outside the submitted work. B.S. Lewis: Lewis reports personal fees from Kiniksa Pharmaceuticals during the conduct of the study. L. Zou: Zou reports personal fees and others from Kiniksa Pharmaceuticals outside the submitted work. S.J. Nicholls: Nicholls reports grants and personal fees from Kiniksa Pharmaceuticals during the conduct of the study; grants and personal fees from AstraZeneca, Anthera, Resverlogix, Sanofi-Regeneron, and Esperion; personal fees from Akcea, Eli Lilly, Omthera, Merck, Takeda, CSL Behring, and Boehringer Ingelheim; and grants from Amgen, Novartis, Abionyx (formerly Cerenis), The Medicines Company, Liposcience, Roche, and InfraReDx outside the submitted work. A.L. Klein: Klein reports grants and others from Kiniksa Pharmaceuticals during the conduct of the study and other fees from Cardiol Therapeutics, SOBI Pharmaceuticals, and Pfizer Pharmaceuticals outside the submitted work. M. Imazio: Imazio reports no disclosures. J.F. Paolini: Paolini reports personal fees and others from Kiniksa Pharmaceuticals outside the submitted work and is a patent inventor on pending patent applications licensed to Kiniksa Pharmaceuticals covering methods of using rilonacept for treating RP., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
41. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
- Author
-
Eikelboom JW, Bosch J, Connolly SJ, Tyrwitt J, Fox KAA, Muehlhofer E, Neumann C, Tasto C, Bangdiwala SI, Diaz R, Alings M, Dagenais GR, Leong DP, Lonn EM, Avezum A, Piegas LS, Widimsky P, Parkhomenko AN, Bhatt DL, Branch KRH, Probstfield JL, Lopez-Jaramillo P, Rydén L, Pogosova N, Keltai K, Keltai M, Ertl G, Stoerk S, Dans AL, Lanas F, Liang Y, Zhu J, Torp-Pedersen C, Maggioni AP, Commerford PJ, Guzik TJ, Vanassche T, Verhamme P, O'Donnell M, Tonkin AM, Varigos JD, Vinereanu D, Felix C, Kim JH, Ibrahim KS, Lewis BS, Metsarinne KP, Aboyans V, Steg PG, Hori M, Kakkar A, Anand SS, Lamy A, Sharma M, and Yusuf S
- Subjects
- Humans, Infant, Aspirin, Drug Therapy, Combination, Rivaroxaban, Myocardial Infarction epidemiology, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease drug therapy, Peripheral Arterial Disease epidemiology, Stroke epidemiology
- Abstract
Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE)., Methods and Results: Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1-1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11-2.61], mortality 1.87 (1.65-2.10), stroke 0.62 (0.50-0.76), and MI 1.02 (0.86-1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86-1.19) and 2.49 (2.24-2.75), compared with 1.67 (1.48-1.87) and 5.11 (95% CI 4.77-5.47), respectively, during the randomized treatment phase with the combination., Conclusion: In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
42. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events.
- Author
-
Tamargo J, Kaski JC, Kimura T, Barton JC, Yamamoto K, Komiyama M, Drexel H, Lewis BS, Agewall S, and Hasegawa K
- Subjects
- Clopidogrel, Fibrinolytic Agents adverse effects, Humans, Imidazoles, Lipids, Organosilicon Compounds, Warfarin, Cardiovascular Agents, Cardiovascular Diseases, Coronary Artery Disease drug therapy, Coronary Artery Disease genetics, Hemostatics, Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Abstract
Awareness of racial/ethnic disparities represents a key challenge for healthcare systems that attempt to provide effective healthcare and to reduce existing inequalities in the use of and adherence to guideline-recommended cardiovascular drugs to improve clinical outcomes for cardiovascular disease (CVD). In this review, we describe important racial/ethnic differences between and within ethnic groups in the prevalence, risk factors, haemostatic factors, anti-inflammatory and endothelial markers, recurrence, and outcomes of CVD. We discuss important differences in the selection, doses, and response [efficacy and adverse drug reactions (ADRs)] in ethnically diverse patients treated with antithrombotics or lipid-lowering drugs. Differences in drug response are mainly related to racial/ethnic differences in the frequency of polymorphisms in genes encoding drug-metabolizing enzymes (DMEs) and drug transporters. These polymorphisms markedly influence the pharmacokinetics, dose requirements, and safety of warfarin, clopidogrel, and statins. This review aims to support a better understanding of the genetic differences between and among populations to identify patients who may experience an ADR or a lack of drug response, thus optimizing therapy and improving outcomes. The greater the understanding of the differences in the genetic variants of DMEs and transporters that determine the differences in the exposure, efficacy, and safety of cardiovascular drugs between races/ethnicities, the greater the probability that personalized medicine will become a reality., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
43. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial.
- Author
-
De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, and Wallentin L
- Subjects
- Anticoagulants adverse effects, Humans, Hypoglycemic Agents adverse effects, Risk Factors, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Diabetes Mellitus diagnosis, Diabetes Mellitus drug therapy, Diabetes Mellitus epidemiology, Embolism epidemiology, Insulins therapeutic use, Myocardial Infarction diagnosis, Myocardial Infarction epidemiology, Stroke diagnosis, Stroke epidemiology, Stroke prevention & control
- Abstract
Aims: Whether diabetes without insulin therapy is an independent cardiovascular (CV) risk factor in atrial fibrillation (AF) has recently been questioned. We investigated the prognostic relevance of diabetes with or without insulin treatment in patients in the ARISTOTLE trial., Methods and Results: Patients with AF and increased stroke risk randomized to apixaban vs. warfarin were classified according to diabetes status: no diabetes; diabetes on no diabetes medications; diabetes on non-insulin antidiabetic drugs only; or insulin-treated. The associations between such patient subgroups and stroke/systemic embolism (SE), myocardial infarction (MI), and CV death were examined by Cox proportional hazard regression, both unadjusted and adjusted for other prognostic variables. Patients with diabetes were younger and had a higher body mass index. Median CHA2DS2VASc score was 4.0 in patients with diabetes and 3.0 in patients without diabetes. We found no significant difference in stroke/SE incidence across patient subgroups. Compared with no diabetes, only insulin-treated diabetes was significantly associated with higher risk. When adjusted for clinical variables, compared with no diabetes, the hazard ratios (HRs) for MI (95% confidence intervals) were for diabetes on no medication: 1.15 (0.62-2.14); for diabetes on non-insulin antidiabetic drugs: 1.32 (0.90-1.94); for insulin-treated diabetes: 2.34 (1.43-3.82); interaction P = 0.008. HRs for CV death were for diabetes on no medication: 1.19 (0.86-166); for diabetes on non-insulin antidiabetic drugs: 1.12 (0.88-1.42); for insulin-treated diabetes 1.85 (1.36-2.53), interaction P = 0.001., Conclusion: In anticoagulated patients with AF, a higher risk of MI and CV death is largely confined to diabetes treated with insulin., (© The Author(s) 2020. Published on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
44. Are SGLT2 inhibitors effective against 'all' heart failure with preserved ejection fraction?
- Author
-
Hasegawa K and Lewis BS
- Subjects
- Humans, Stroke Volume, Ventricular Function, Left, Heart Failure diagnosis, Heart Failure drug therapy, Sodium-Glucose Transporter 2 Inhibitors adverse effects
- Published
- 2022
- Full Text
- View/download PDF
45. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy.
- Author
-
Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, and Agewall S
- Subjects
- Humans, Randomized Controlled Trials as Topic, Cardiovascular System
- Published
- 2022
- Full Text
- View/download PDF
46. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing.
- Author
-
El Hadidi S, Rosano G, Tamargo J, Agewall S, Drexel H, Kaski JC, Niessner A, Lewis BS, Coats AJS, and Savarese G
- Subjects
- Humans, Inappropriate Prescribing prevention & control, Polypharmacy, Stroke Volume, Cardiology, Heart Failure diagnosis, Heart Failure drug therapy
- Abstract
Heart failure (HF) is a chronic debilitating and potentially life-threatening condition. HF patients are usually at high risk of polypharmacy and consequently, potentially inappropriate prescribing leading to poor clinical outcomes. Based on the published literature, a comprehensive HF-specific prescribing review tool is compiled to avoid medications that may cause HF or harm HF patients and to optimize the prescribing practice of HF guideline-directed medical therapies. Recommendations are made in line with the last versions of European Society of Cardiology (ESC) guidelines, ESC position papers, scientific evidence, and experts' opinions., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
47. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, and Caulfield MJ
- Subjects
- Europe, Humans, Pharmacogenetics, Cardiology, Cardiovascular System
- Abstract
Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
48. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, and Caulfield MJ
- Subjects
- Europe, Humans, Pharmacogenetics, Cardiology, Cardiovascular System, Heart Failure
- Abstract
There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. However, there is no common position taken by international cardiovascular societies to unite diverse availability, interpretation, and application of such data, nor is there recognition of the challenges of variation in clinical practice between countries within Europe. Aside from the considerable barriers to implementing pharmacogenomic testing and the complexities of clinically actioning results, there are differences in the availability of resources and expertise internationally within Europe. Diverse legal and ethical approaches to genomic testing and clinical therapeutic application also require serious thought. As direct-to-consumer genomic testing becomes more common, it can be anticipated that data may be brought in by patients themselves, which will require critical assessment by the clinical cardiovascular prescriber. In a modern, pluralistic and multi-ethnic Europe, self-identified race/ethnicity may not be concordant with genetically detected ancestry and thus may not accurately convey polymorphism prevalence. Given the broad relevance of pharmacogenomics to areas, such as thrombosis and coagulation, interventional cardiology, heart failure, arrhythmias, clinical trials, and policy/regulatory activity within cardiovascular medicine, as well as to genomic and pharmacology subspecialists, this position statement attempts to address these issues at a wide-ranging level., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
49. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
- Author
-
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabés JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylén I, Tolosana JM, Leyva F, Linde C, Abdelhamid M, Aboyans V, Arbelo E, Asteggiano R, Barón-Esquivias G, Bauersachs J, Biffi M, Birgersdotter-Green U, Bongiorni MG, Borger MA, Čelutkienė J, Cikes M, Daubert JC, Drossart I, Ellenbogen K, Elliott PM, Fabritz L, Falk V, Fauchier L, Fernández-Avilés F, Foldager D, Gadler F, De Vinuesa PGG, Gorenek B, Guerra JM, Hermann Haugaa K, Hendriks J, Kahan T, Katus HA, Konradi A, Koskinas KC, Law H, Lewis BS, Linker NJ, Løchen ML, Lumens J, Mascherbauer J, Mullens W, Nagy KV, Prescott E, Raatikainen P, Rakisheva A, Reichlin T, Ricci RP, Shlyakhto E, Sitges M, Sousa-Uva M, Sutton R, Suwalski P, Svendsen JH, Touyz RM, Van Gelder IC, Vernooy K, Waltenberger J, Whinnett Z, and Witte KK
- Subjects
- Cardiac Pacing, Artificial, Humans, Stroke Volume, Atrial Fibrillation therapy, Cardiac Resynchronization Therapy adverse effects, Heart Failure diagnosis, Heart Failure therapy
- Published
- 2022
- Full Text
- View/download PDF
50. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, and Torp-Pedersen C
- Subjects
- Goals, Humans, Potassium, Cardiology, Cardiovascular Diseases diagnosis, Cardiovascular Diseases drug therapy, Cardiovascular Diseases epidemiology, Hypokalemia diagnosis, Hypokalemia drug therapy
- Abstract
Hypokalaemia is common in patients with cardiovascular disease. In this review, we emphasize the importance of tight potassium regulation in patients with cardiovascular disease based on findings from observational studies. To enhance the understanding, we also describe the mechanisms of potassium homeostasis maintenance, the most common causes of hypokalaemia and present strategies for monitoring and management of low potassium levels. We propose elevation of potassium in asymptomatic patients with lower normal concentrations and concurrent cardiovascular disease. These proposals are intended to assist clinicians until more evidence is available., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.